Silybin Meglumine Tablets
Function and Efficacy
Animal experiments show that this product can increase the activity of microsomal enzymes in liver cells and accelerate the liver's detoxification ability; it can also reduce the increase in serum glutamic-alanine aminotransferase in rats caused by carbon tetrachloride; it can also stabilize cell membranes of various types of liver damage caused by liver poisons such as carbon tetrachloride, phalloidine, thioacetamide, and crotalurine, thereby achieving a significant liver protection effect.
Ingredients
The active ingredient of this product is silybin meglumine.
Appearance
This product is a film-coated tablet, which appears light yellow after removing the coating.
Indication
Used for adjuvant treatment of acute and chronic hepatitis, early cirrhosis, and toxic liver damage.
Usage and Dosage
Oral administration: 3 times a day, 100-200 mg each time, or as directed by a physician.
Adverse Reactions
Occasionally, there are reactions such as dizziness and upper abdominal discomfort.
Precautions
Not yet clear.
Special Population Medication
Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.
Drug Interactions
Not yet clear.
Storage
Keep away from light, sealed and stored in a dry place.
Packaging Specification
50mg
Validity Period
Tentatively 24 months.
Manufacturer
Zhejiang Dongri Pharmaceutical Co., Ltd.
-
Founded in:
2003-01-28 -
Address:
Wuchi Industrial Park, Yongjia County, Zhejiang Province -
Tax NO.:
91330300736028890E -
Registered Funds:
49.6375 million yuan -
Website:
-
Email: